These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29050547)

  • 21. Novel Technology to Assess Programmed Death-Ligand 1 Expression by Multiplex Immunofluorescence and Image Analysis.
    Parra ER
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e22-e24. PubMed ID: 29189262
    [No Abstract]   [Full Text] [Related]  

  • 22. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.
    Witkowska M; Smolewski P
    J Immunol Res; 2018; 2018():1982423. PubMed ID: 29850620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 27. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?
    Snyder A; Pamer E; Wolchok J
    Science; 2015 Nov; 350(6264):1031-2. PubMed ID: 26612936
    [No Abstract]   [Full Text] [Related]  

  • 28. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunocheckpoints in modern oncology: the next 15 years.
    Massari F; Santoni M; Ciccarese C; Santini D
    Expert Opin Biol Ther; 2015 Jul; 15(7):917-21. PubMed ID: 26063384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].
    Berghmans T; Grigoriu B; Sculier JP; Meert AP
    Rev Mal Respir; 2018 Feb; 35(2):197-205. PubMed ID: 29395567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: translational medicine is promoting cross-talk of inter discipline.
    Yu Y
    Anticancer Agents Med Chem; 2013 Feb; 13(2):193-4. PubMed ID: 22934704
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors in renal cell carcinoma.
    Ross K; Jones RJ
    Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
    Smit EF; van den Heuvel MM
    Lancet; 2016 Apr; 387(10030):1795-6. PubMed ID: 26972842
    [No Abstract]   [Full Text] [Related]  

  • 38. Heather Wakelee on the Role of Checkpoint Inhibitors in Advanced Lung Cancer.
    Wakelee H
    Oncology (Williston Park); 2017 Jun; 31(6):440, 442. PubMed ID: 28620899
    [No Abstract]   [Full Text] [Related]  

  • 39. Reporter nanoparticle that monitors its anticancer efficacy in real time.
    Kulkarni A; Rao P; Natarajan S; Goldman A; Sabbisetti VS; Khater Y; Korimerla N; Chandrasekar V; Mashelkar RA; Sengupta S
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2104-13. PubMed ID: 27036008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In process].
    Hille-Rehfeld A
    Med Monatsschr Pharm; 2016 Oct; 39(10):444-5. PubMed ID: 29979543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.